PMID- 10510669
OWN - NLM
STAT- MEDLINE
DCOM- 19991019
LR  - 20190513
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 112
IP  - 4
DP  - 1999 Oct
TI  - Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 
      overexpression, and HER-2/neu gene amplification detected by fluorescence in situ 
      hybridization in breast cancer.
PG  - 459-69
AB  - The HER-2/neu oncogene, localized to chromosome 17q, shares substantial homology 
      with the epidermal growth factor receptor. HER-2/neu gene amplification and 
      protein overexpression have been associated with poor prognosis in breast cancer. 
      Formalin-fixed paraffin-embedded primary invasive breast cancer tissues from 135 
      women were tested for HER-2/neu gene amplification by automated fluorescence in 
      situ hybridization (FISH) using a sequence probe. The tumors also were evaluated 
      by immunohistochemistry for proliferation markers Ki 67 (MIB1) and p34cdc2 
      cyclin-dependent kinase. Patients were followed up for a mean of 61 months. There 
      were 70 node-negative and 65 node-positive cases. Ki 67 and p34cdc2 proliferation 
      marker overexpression, HER-2/neu oncogene amplification, large tumor size, high 
      tumor grade, advanced tumor stage, positive lymph node status, and distant 
      metastasis at the time of diagnosis predicted disease-related death in combined 
      node-negative and node-positive breast cancer. HER-2/neu gene amplification, 
      tumor stage, lymph node metastasis, tumor grade, and distant metastasis at the 
      time of diagnosis independently predicted disease outcome. HER-2/neu 
      amplification detected by FISH also predicted disease-related death independent 
      of lymph node status, tumor grade, and distant metastasis in breast cancer 
      patients who received adjuvant therapy.
FAU - Depowski, P L
AU  - Depowski PL
AD  - Department of Pathology, Albany Medical Center, NY 12208, USA.
FAU - Brien, T P
AU  - Brien TP
FAU - Sheehan, C E
AU  - Sheehan CE
FAU - Stylos, S
AU  - Stylos S
FAU - Johnson, R L
AU  - Johnson RL
FAU - Ross, J S
AU  - Ross JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Antigens, Nuclear)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.22 (CDC2 Protein Kinase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Nuclear
MH  - Breast Neoplasms/*chemistry/genetics
MH  - CDC2 Protein Kinase/*analysis/genetics
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Ki-67 Antigen/*analysis/genetics
MH  - Lymph Nodes/pathology
MH  - Middle Aged
MH  - Nuclear Proteins/*chemistry/genetics
MH  - Prognosis
MH  - Receptor, ErbB-2/*analysis/genetics
MH  - Receptors, Estrogen/analysis
MH  - Receptors, Progesterone/analysis
EDAT- 1999/10/08 00:00
MHDA- 1999/10/08 00:01
CRDT- 1999/10/08 00:00
PHST- 1999/10/08 00:00 [pubmed]
PHST- 1999/10/08 00:01 [medline]
PHST- 1999/10/08 00:00 [entrez]
AID - 10.1093/ajcp/112.4.459 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1999 Oct;112(4):459-69. doi: 10.1093/ajcp/112.4.459.